The novel natural antibiotics pyloricidin A, B and C, consisting of a common peptidic moiety (pyloricidin A: L-valine-L-valine-L-leucine; pyloricidin B: L-valine-L-leucine; pyloricidin C: L-leucine), exhibit potent and highly selective anti-Helicobacter pylori activity. In order to develop more potent compounds and to investigate structure activity relationships for the peptidic moiety with regard to the combination of amino acids, a series of derivatives with various dipeptidic moieties were prepared and evaluated for their anti-H. pylori activity. The combination of the two amino acids in the moiety was found to have a significant effect on the activity; the compound with Nva-Abu showed excellent anti-H pylori activity with an MIC
60% clearance of H. pylori from infected Mongolian gerbils upon repetitive oral administration (10mg/kg, b. i. d. for 7 days).
Helicobacter pylori, a Gram-negative bacterium, plays a crucial role in the pathogenesis of gastric and duodenal ulcers.1-7) Therefore, eradication of this organism is of great importance in treating peptic ulcers. In our program to develop therapeutically useful anti-H. pylori agents, promising lead compounds, pyloricidin A, B and C, were discovered in Takeda's pharmaceutical discovery center. 8, 9) In order to investigate structure activity relationships, initially, we carried out chemical modification of the common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexa-structural unit is the minimum component required to express anti-H. pylori activity.10) Next, we focused on the terminal peptidic moiety. A series of pyloricidin B and pyloricidin C derivatives, in which the terminal L-valine and L-leucine were substituted with various amino acids, were prepared and evaluated for their anti-H. pylori activity.
As a result, it was clear that the L-valine and L-leucine the activity was largely associated with the amino acids introduced; the allylglycine ((allyl)Gly) derivative 1A exhibited the most potent activity, which was 60-fold greater than that of the lead compound pyloricidin C.11) Based on these findings, we speculated that the fixed L-leucine residue in the pyloricidin B derivatives could be substituted with other amino acids. Furthermore, considering that the anti-H. pylori activity of pyloricidin B derivatives is generally superior to that of pyloricidin C, we anticipated that more potent derivatives might be prepared by elongation of the peptidic moiety of 1A with an appropriate amino acid. Therefore, we prepared a series of derivatives with X-(allyl)Gly (X=norvaline (Nva), Ile, Met, (allyl)Gly, Asn and S-methylcysteine (Cys(Me)) as the terminal dipeptidec moiety. In addition, to elucidate how the combination of amino acids in the peptidic moiety affects the anti-H. pylori activity, a series of derivatives, possessing the dipeptides Nva-Y (Y=Ala, (S)-2-aminobutyric acid (Abu), Nva, Gln and Met), were also prepared. In this paper, we report the synthesis and anti-H. pylori activity of these derivatives as well as the in vivo clearance of H.
pylori by the repetitive oral administration of the selected compound 2aC to Mongolian gerbils infected with H.
pylori TN2GF4.
Chemistry
The derivatives 2aA-fA and 2aB-aF, bearing X-(allyl)Gly (X=Nva, Ile, Met, (allyl)Gly, Asn and Cys(Me)) and Nva-Y (Y=Ala, Abu, Nva, Gln and Met), were prepared as shown in Scheme 1. The derivatives 2aA-fA were obtained by the condensation of the Nhyroxysuccinimide esters (Boc-X-OSu) derived from the Boc protected amino acids (Boc-X) with the (allyl)Gly derivative 1A,11) followed by removal of the Boc protecting groups. The derivatives 2aB-aF were prepared as follows. The Boc protected dipeptides (Boc-Nva-Y) were coupled with the benzhydryl ester 4 using water soluble hydroxybenzotriazole (HOBt) to give 5aB-aF, which were treated with 4N HCl/EtOAc to afford the desired compounds 2aB-aF. observations allowed us to speculate that each amino acid in the peptidic moiety affects the conformation of the other, which might reflect the potency of the anti-H. pylori activity.
Results and Discussion
So far, the best results for eradication of H. pylori have been achieved by combination therapy, involving concomitant administration of a proton pump inhibitor and antimicrobial agents (clarithromycin (CAM) and metronidazole (MNZ), or CAM and amoxicillin (AMPC)).
However, recently, GOTOH et al. reported that of 63 clinical isolates of H. pylori, 9.5% and 7.9% of the strains displayed drug resistance to CAM and MNZ, respectively.12) VAN ZWET et al. also reported the emergence of an AMPC resistant strain.13) In addition, H. pylori strains show a high degree of diversity at the genetic level,14) which might cause a difference in the susceptibility of strains to antimicrobial agents. Therefore, any anti-H. pylori agent with therapeutic usefulness should have potent activity against various strains, including the drug resistant strains. Accordingly, we evaluated the anti-H, pylori activity of 2aC against 54 clinical isolates including the CAM resistant strain (TN352) and the MNZ resistant strain (TN309) and compared its potency with those of AMPC, CAM and MNZ. The range of MICs and the concentrations of agents required to inhibit 50% and 90% of strains are shown in Next, we assessed the antibacterial selectivity of 2aC. Considering that pyloricidin A, B and C also showed highly specific anti-H. pylori activity, it is speculated that the antibacterial selectivity observed in pyloricidin antibiotics is attributed to the common (2S,3R,4R,5S)-5-amino-2,3,4,6and AMPC have broad antibacterial spectra and therefore affect gastrointestinal microflora, which would cause gastrointestinal side effects.15) As the antibacterial spectra of 2aC is restricted to H. pylori, its oral use is expected to have less side effects. On the basis of the anti-H. pylori activity, we selected 2aC as a test compound for the in vivo clearance of H. pylori-associated gastritis in humans. Therefore, we carried out in vivo clearance experiments using Mongolian gerbils infected with H. pylori TN2GF4 for 4 weeks. Table 4 shows the clearance rate and the bacterial recovery after repetitive oral administration of 2aC (10mg/kg, twice a day for 7 days). Complete clearance of H. pylori was achieved in 3 of the 5 animals (clearance rate: 60%) and a significant decrease of bacterial recovery was observed in the remaining animals. From these results, it was confirmed that compound 2aC could effectively eradicate H. pylori from infected Mongolian gerbils by oral administration. These findings together with the antibacterial profiles described above suggest that compound 2aC is a promising agent for the treatment of H. pylori infection. Table 5 . A series of compounds 2aC-aF were prepared in a similar manner to that employed for the preparation of 2aB
and their yields and physicochemical data are listed in Table 5 . was warmed to room temperature and stirred for 18 hours. After removal of solvent under reduced pressure, the residue was extracted with EtOAc-H2O. The organic layer was washed with 5% aqueous citric acid, saturated aqueous NaHCO3 and brine, and then dried over Na2SO4 and concentrated. The residue was recrystallized from EtOAc to give 5aB (281mg, 79%) as a colorless solid.
Compounds 5aC-aF were prepared by a similar procedure to that used for the preparation of SaB. Their yields and physicochemical data are listed in Table 6 . MICs were defined as the lowest concentrations of the compounds preventing visible bacterial growth after four days of incubation. In Vivo Clearance of H. pylori TN2GF4
Five-week-old MON/Jms/Gbs Slc Mongolian gerbils (SLC Japan Inc., Shizuoka, Japan) were inoculated intragastrically with 107.61 cfu of H. pylori TN2GF4. Four weeks after infection, compound 2aC was administered orally at a dose of 10mg/kg twice a day for 7 days in the form of a solution in 0.5% aqueous methylcellulose. One day after administration of the final dose, the animals were killed and the stomachs were removed. Each stomach was homogenized with Brucella broth and serial dilutions were plated on modified Skirrow's medium. The plates were in GasPak jars. The viable cell counts for each gastric wall were calculated by counting the number of colonies on the agar plates.
